These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
365 related items for PubMed ID: 28000240
21. A case of toxic epidermal necrolysis associated with lenvatinib and sintilimab therapy for intrahepatic cholangiocarcinoma. Gong Y, Mao J, Liu M, Gao J. J Int Med Res; 2023 May; 51(5):3000605231173556. PubMed ID: 37211771 [Abstract] [Full Text] [Related]
23. Striking enhancement at the site of radiation for nivolumab-induced Stevens-Johnson syndrome. Shah KM, Rancour EA, Al-Omari A, Rahnama-Moghadam S. Dermatol Online J; 2018 Jun 15; 24(6):. PubMed ID: 30142712 [Abstract] [Full Text] [Related]
24. Granulomatous/sarcoid-like reactions in the setting of programmed cell death-1 inhibition: a potential mimic of disease recurrence. Hiraki T, Hatanaka M, Arimura A, Kawahira H, Kirishima M, Kitazono I, Horinouchi M, Higashi M, Kanekura T, Tanimoto A. J Cutan Pathol; 2020 Feb 15; 47(2):154-160. PubMed ID: 31437317 [Abstract] [Full Text] [Related]
25. [Varied immuno-related adverse events induced by immune-check point inhibitors - Nivolumab-associated psoriasiform dermatitis related with increased serum level of interleukin-6]. Okiyama N, Tanaka R. Nihon Rinsho Meneki Gakkai Kaishi; 2017 Feb 15; 40(2):95-101. PubMed ID: 28603207 [Abstract] [Full Text] [Related]
26. Nivolumab-induced vitiligo in a metastatic melanoma patient: A case report. Edmondson LA, Smith LV, Mallik A. J Oncol Pharm Pract; 2017 Dec 15; 23(8):629-634. PubMed ID: 27609337 [Abstract] [Full Text] [Related]
27. [Not Available]. Mateus C, Libenciuc C, Robert C. Bull Cancer; 2016 Jun 15; 103(6 Suppl 1):S4-S11. PubMed ID: 27494973 [Abstract] [Full Text] [Related]
28. The safety of anti PD-1 therapeutics for the treatment of melanoma. Ramelyte E, Schindler SA, Dummer R. Expert Opin Drug Saf; 2017 Jan 15; 16(1):41-53. PubMed ID: 27737598 [Abstract] [Full Text] [Related]
29. Grover's-like drug eruption in a patient with metastatic melanoma under ipilimumab therapy. Koelzer VH, Buser T, Willi N, Rothschild SI, Wicki A, Schiller P, Cathomas G, Zippelius A, Mertz KD. J Immunother Cancer; 2016 Jan 15; 4():47. PubMed ID: 27532022 [Abstract] [Full Text] [Related]
30. Steven-Johnson Syndrome: A Rare but Serious Adverse Event of Nivolumab Use in a Patient With Metastatic Gastric Adenocarcinoma. Saad E, Adhikari P, Antala D, Abdulrahman A, Begiashvili V, Mohamed K, Ali E, Zhang Q. J Med Cases; 2022 Sep 15; 13(9):449-455. PubMed ID: 36258702 [Abstract] [Full Text] [Related]
38. Toxic epidermal necrolysis accompanied by several immune-related adverse events developed after discontinuation of nivolumab. Watanabe Y, Yamaguchi Y, Takamura N, Takahashi Y, Aihara M. Eur J Cancer; 2020 May 15; 131():1-4. PubMed ID: 32248069 [No Abstract] [Full Text] [Related]